Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 4Barrett Esophagus 4Uterine Cervical Neoplasms 2Uterine Cervical Dysplasia 2Mouth Neoplasms 2Uterine Neoplasms 1Oral Lesions 1Neoplasms, Squamous Cell 1Mouth Diseases 1Malignant Neoplasms of Female Genital Organs 1Laryngeal Diseases 1Head and Neck Neoplasms 1Gastroesophageal Reflux 1Endometrial Neoplasms 1Colonic Polyps 1Carcinoma, Squamous Cell 1Carcinoma in Situ 1

Interventions

Paclitaxel 13pembrolizumab 8Carboplatin 7Surveys and Questionnaires 6Cisplatin 6Brachytherapy 5Doxorubicin 4Docetaxel 4Pemetrexed 3Hyperthermic Intraperitoneal Chemotherapy 3Gemcitabine 3FANG vaccine 3Biopsy 3osimertinib 2olaparib 2niraparib 2durvalumab 2adavosertib 2Trastuzumab 2Topotecan 2Taxes 2Standard of Care 2Sentinel Lymph Node Biopsy 2Saline Solution 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Oxaliplatin 2Nivolumab 2Music Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Neoplasms × Proflavine × Clear all
NCT02095847 2015-04-08

High-Resolution Microendoscopy to Guide Hysteroscopic Tumor Resection

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gynecologic

Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡